quinazolines has been researched along with Hepatocellular Carcinoma in 158 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (3.80) | 18.7374 |
| 1990's | 6 (3.80) | 18.2507 |
| 2000's | 43 (27.22) | 29.6817 |
| 2010's | 84 (53.16) | 24.3611 |
| 2020's | 19 (12.03) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Gayyar, MMH; Alattar, A; Alshaman, R; Hamdan, AM | 1 |
| Bae, SJ; Kim, YW; Song, YR; Yun, UJ | 1 |
| Che, J; Dong, X; Du, J; Gao, J; He, Q; Lu, Y; Luo, M; Luo, P; Nie, W; Pan, C; Wang, J; Zhu, H | 1 |
| Atkinson, D; Bandula, S; Bascal, ZA; Beaton, L; Boucher, E; Chouhan, M; Clarkson, MJ; Cooper, S; Counsell, N; Czuczman, P; Davidson, BR; Forsyth, S; Hague, J; Hartley, JA; Jansen, M; Lewis, AL; Lowe, HL; Meyer, T; Munneke, G; Pollok, JM; Raja, J; Ryan, S; Sharma, D; Sharma, RA; Stuckey, DJ; Thin, MZ; Tregidgo, HFJ; Wilde, PE; Znati, SA | 1 |
| Bi, Y; Han, X; Jiao, D; Ren, J; Wang, Y | 1 |
| Bi, Y; Han, X; Jiao, D; Ren, J | 1 |
| Cui, Y; Dai, M; Hu, Y; Kong, W; Wang, X; Wu, H; Wu, J; Yu, B; Yu, X; Zhang, H; Zheng, Y | 1 |
| Bifulco, N; Boral, A; Brooijmans, N; Dorsch, M; Guzi, T; Hatlen, MA; Hoeflich, KP; Kang, YK; Kim, JL; Kim, RD; Lengauer, C; Miduturu, C; Rozsahegyi, E; Rubin, N; Schmidt-Kittler, O; Sheets, MP; Sherwin, CA; Shi, H; Wolf, BB | 1 |
| Chan, SL; Choo, SP; Dufour, JF; Faivre, S; Feun, LG; Hagel, M; Hoeflich, KP; Hollebecque, A; Kang, YK; Kim, RD; Kohl, NE; Lengauer, C; Lim, HY; Lin, ZZ; Llovet, JM; Macarulla, T; Manoogian, M; Mazzaferro, V; Meyer, T; Palmer, DH; Park, JW; Sarker, D; Schmidt-Kittler, O; Sharma, S; Sherwin, CA; Shi, H; Stransky, N; Sung, MW; Trojan, J; Tugnait, M; Wolf, BB; Yau, T; Yen, CJ; Yoon, JH; Zhu, AX | 1 |
| Kim, KW; Van den Abbeele, AD | 1 |
| Chow, EK; Gu, M; Hooi, L; Lim, JJ; Toh, TB; Zhang, X | 1 |
| Cao, J; Chen, Z; Dai, X; Gai, R; He, Q; Luo, H; Qian, M; Yan, F; Yang, B; Ye, S; Ying, M; Yuan, T; Zhu, H | 1 |
| Bu, Y; Chang, F; Jia, F; Jia, Q; Liao, X; Ren, X; Song, G; Xiao, X; Xu, Z; Zhang, M | 1 |
| Gu, ZL; Huang, J; Zhen, LL | 1 |
| Chen, DL; Guo, XX; Hu, L; Jiang, R; Li, DY; Li, J; Li, LS; Ran, JH; Tang, JF; Xu, K; Zeng, D; Zhao, S; Zhou, P | 1 |
| Gao, H; Hao, H; Li, S; Qi, C; Zhang, L; Zong, H | 1 |
| Bosserhoff, A; Dietrich, P; Freese, K; Hellerbrand, C; Seitz, T; Thasler, WE | 1 |
| Cheng, S; Du, C; Fan, X; Fu, J; Gao, Y; Li, N; Ma, J; Markowitz, GJ; Qin, W; Wang, H; Yang, B; Yang, P | 1 |
| Chen, S; Liu, W; Yu, W; Zhang, K | 1 |
| Hwang, S; Kim, I; Kim, K; Kim, S; Park, S; Yeom, J | 1 |
| Chen, J; Jin, F; Song, X; Wang, R; Wang, Y; Wu, Y; Zhu, Y | 1 |
| Carter, R; Hagan, AE; Lewis, AL; Lloyd, AW; Macfarlane, WM; Phillips, GJ; Sharma, RA; Westhorpe, A; Znati, SA | 1 |
| Austin, E; Kalomeris, T; Larimer, B; Mahmood, U; Nesti, S; Sinevici, N; Wehrenberg-Klee, E | 1 |
| Deng, J; Fan, X; Hao, X; Lei, F; Li, J; Liang, Y; Liang, Z; Liu, D; Shi, T; Wang, Z; Wen, H; Zhang, H | 1 |
| Aoyama, K; Chiba, T; Inoue, M; Iwama, A; Koide, S; Kusakabe, Y; Mimura, N; Miyagi, S; Miyazaki, M; Noguchi, Y; Ogasawara, S; Ooka, Y; Oshima, M; Otsuka, M; Saito, T; Saraya, A; Suzuki, E; Tara, S; Tawada, A; Wakamatsu, T; Yokosuka, O; Yokoyama, M; Yuki, K; Zen, Y | 1 |
| Ghosh, B; Keshari, AK; Kumar, D; Kumar, U; Rai, A; Raj, V; Rawat, A; Saha, S; Singh, AK; Trivedi, P | 1 |
| Chang, CJ; Hu, CY; Lin, CH; Su, YC; Wu, CL; Wu, HT | 1 |
| Ding, Q; Li, CY; Wang, Y; Xu, T; Zhang, L; Zhou, DD | 1 |
| Gao, L; Lv, F; Shay, C; Teng, Y; Wang, X | 1 |
| Kim, JH; Kim, SH; Kwon, HY; Lee, JY; Nam, MH; Ryu, DH; Shim, BS | 1 |
| Chen, JL; Hu, X; Li, QY; Li, YL; Rao, MJ; Wu, LW; Yan, W; Zhang, B; Zhang, C; Zhang, NY | 1 |
| Chang, SS; Chao, TI; Chen, KF; Chen, LJ; Hsiao, YJ; Hsieh, FS; Huang, CY; Hung, MH; Kuo, CW; Shih, CT; Tsai, MH | 1 |
| Qian, HL; Xu, S; Zhu, LZ | 1 |
| Chen, DL; Chen, Y; Guo, XX; Jiang, R; Li, DY; Li, J; Li, XP; Lyu, XT; Lyu, YW; Ran, JH; Tian, K; Yuan, DZ; Zhou, P | 1 |
| Chao, D; Liu, K; Pang, L; Shi, Y; Wang, W | 1 |
| Deng, JD; Hu, XL; Jiang, Y; Lei, S; Tan, W; Wang, Z; Wen, HX; Zhang, HH | 1 |
| Kim, I; Kim, SY; Namgung, Y | 1 |
| Ge, K; Jia, C; Lu, J; Zhu, H | 1 |
| Baumert, TF; Duong, FH; Durand, SC; Fofana, I; Heim, MH; Lupberger, J; Pessaux, P; Thumann, C; Xiao, F; Zeisel, MB; Zona, L | 1 |
| Biasco, G; Brandi, G; Dika, E; Maibach, H; Patrizi, A; Venturi, M | 1 |
| Farghaly, TA; Mahmoud, HK | 1 |
| Cheng, AL; Chiou, TJ; Hsu, C; Hsu, CH; Jin, K; Kang, YK; Sandoval-Tan, J; Shao, YY; Shun, CT; Su, WC; Yang, TS | 1 |
| Chen, CH; Chen, LC; Chen, YJ; Chien, PH; Chien, YF; Hsieh, YL; Hsu, SC; Huang, WC; Hung, CM; Lin, YM; Tu, CY | 1 |
| Dong, X; He, C; Jiang, H; Jiang, X; Ma, L; Pan, S; Qiao, H; Sun, X; Tan, G; Wei, Z; Zhai, B; Zhao, D | 1 |
| Edling, CE; Falasca, M; Ghonaim, R; Maffucci, T; Selvaggi, F | 1 |
| Bader, AG; Kelnar, K; Zhao, J | 1 |
| Bardeesy, N; Caravan, P; Chen, X; Crenshaw, A; DePeralta, DK; Fuchs, BC; Fujii, T; Golub, TR; Gupta, S; Hoshida, Y; Kuroda, T; Lanuti, M; Lauwers, GY; McGinn, CM; Onofrio, R; Schmitt, AD; Tanabe, KK; Taylor, B; Wei, L; Winckler, W; Yamada, S | 1 |
| Geissler, M; Steins, M; Thomas, M | 1 |
| Dong, JZ; Lu, MQ; Wang, LP; Zhang, SN; Zou, ZL | 1 |
| Fuchs, BC; Hoshida, Y; Tanabe, KK | 1 |
| Amore, E; Azzolina, A; Bondì, ML; Botto, C; Cervello, M; Craparo, EF; Giammona, G | 1 |
| Chen, YJ; Chi, CW; Huang, HL; Su, WC | 1 |
| Chao, TT; Chen, KF; Chen, YL; Chu, PY; Hung, MH; Liu, CY; Shiau, CW; Wang, CY; Yu, HC | 1 |
| Cui, A; Hou, J; Hua, H; Jiang, Y; Luo, T; Song, P | 1 |
| Bruix, J; Carrilho, FJ; Evans, TR; Jensen, M; Kang, YK; Leberre, MA; Llovet, JM; Meinhardt, G; Qin, S; Rosmorduc, O; Ross, PJ; Santoro, A; Thuluvath, PJ; Zhu, AX | 1 |
| Chu, JH; Cui, SX; Qu, XJ; Song, ZY; Zhang, YS | 1 |
| Choi, SJ; Gu, HR; Han, CJ; Jeong, JH; Kim, J; Kim, YC; Kim, YJ; Lee, JC; No, SH; Noh, GY; Park, SC; Yang, KY | 1 |
| Carella, N; Carr, BI; Cavallini, A; D'Alessandro, R; Lippolis, C; Messa, C; Refolo, MG | 1 |
| Bae, JS; Choi, YS; Lee, SH; Lee, YM; Oh, SY; Seok, JY | 1 |
| Chen, JY; Chen, WS; Chen, YJ; Huang, WC; Yen, CJ | 1 |
| Chen, M; He, Q; Luo, P; Peng, X; Shao, J; Xu, L; Xu, Z; Yang, B; Zhu, H; Zhu, Y | 1 |
| Chen, KF; Chen, YL; Chu, PY; Hung, MH; Shiau, CW; Shih, CT; Tai, WT; Yu, HC | 1 |
| Sun, J; Zhan, C; Zhang, Y; Zhao, H; Zhao, L | 1 |
| Chen, C; Cheng, L; Fan, L; Hu, T; Lu, J; Lu, X; Ma, Y; Ni, B; Ou, S; Qi, F; Yi, X; Yu, L; Zhang, C; Zhao, C; Zheng, Z | 1 |
| Li, J; Liu, Z; Lu, D; Wang, H; Wang, J; Wei, X; Xie, H; Xu, X; Zheng, S; Zhuang, R | 1 |
| Liu, Q; Liu, Y; Luo, F; Shi, L; Yang, F; Zhang, F; Zou, M | 1 |
| Huang, XX; Mao, SS; Wu, JS; Xiong, J; Yu, XN | 1 |
| Hsu, FT; Pan, PJ; Tsai, JJ | 1 |
| Chen, L; Gonzalez, FJ; Gu, J; Hu, CL; Hu, L; Li, L; Li, S; Lin, XM; Liu, JF; Tang, J; Wang, HY; Wang, RY; Wu, MC; Yan, XZ; Zhang, BH; Zhou, WP; Zhu, YJ | 1 |
| Czuczman, P; Hagan, A; Lewis, AL; Lloyd, AW; Macfarlane, WM; Phillips, GJ | 1 |
| Ji, L; Liang, T; Shen, Y; Shi, L; Xu, L; Yang, F; Zhang, G; Zhu, F | 1 |
| Chiang, SY; Chou, ST; Ho, TY; Hsiang, CY; Hsieh, CL; Huang, HF; Lai, MT; Lo, HY | 1 |
| Han, X; Peng, JY; Qi, Y; Wang, XN; Xu, LN; Xu, YW; Yin, LH | 1 |
| Bertran, E; Caja, L; Carmona-Cuenca, I; Fabregat, I; Murillo, MM; Sancho, P | 1 |
| Abbruzzese, J; Chadha, R; Davila, M; Glover, K; Iwasaki, M; Kaseb, A; Kaur, H; Lin, E; Morris, JS; Thomas, MB | 1 |
| Denzlinger, C; Hass, HG | 1 |
| Belani, CP; Dancey, J; Gandara, DR; Gandour-Edwards, R; Iqbal, S; Kindler, HL; Lenz, HJ; Longmate, J; Lurje, G; Mack, PC; Ramanathan, RK; Singh, DA; Tanaka, M; Yen, Y | 1 |
| Finn, RS; Zhu, AX | 1 |
| Chang, CH; Chang, JW; Hui, CY; Yang, CH | 1 |
| Baron, A; Bladt, F; Blivet-Van Eggelpoël, MJ; Desbois-Mouthon, C; Fartoux, L; Housset, C; Rosmorduc, O; Venot, C | 1 |
| Balint, C; Bekaii-Saab, T; Campbell, A; Chen, H; Culler, K; Dai, Z; Dancey, J; Eng, C; Grever, M; Heerema, N; Lee, RM; Markowitz, J; O'Neil, B; Papp, A; Prescott, N; Sadee, W; Villalona-Calero, M; Wei, L; Zalupski, M | 1 |
| Aihara, A; Arii, S; Ito, K; Kudo, A; Matsumura, S; Mitsunori, Y; Murakata, A; Nakamura, N; Noguchi, N; Tanaka, S; Yasen, M | 1 |
| Chen, W; Chen, WC; Hsia, TC; Lai, HC; Shih, CM; Tseng, GC | 1 |
| Li, X; Li, Z; Lv, Y; Ma, Y; Yi, S; Yuan, A | 1 |
| Hagymási, K; Tulassay, Z | 1 |
| Bertran, E; Caja, L; Campbell, J; Fabregat, I; Fausto, N | 1 |
| Chung, YH; Kim, KH; Kim, KM; Lee, D; Lee, HC; Lee, SG; Lee, YJ; Lee, YS; Lim, YS; Park, YK; Shim, JH; Suh, DJ | 1 |
| Chang, CS; Chao, DC; Ho, TY; Hsiang, CY; Huang, HC; Kao, ST; Liang, JA; Lin, LJ; Wu, SL | 1 |
| Abe, M; Hashimoto, O; Inoue, K; Iwamoto, H; Kerbel, RS; Koga, H; Kurogi, J; Kuwahara, R; Nakamura, T; Niizeki, T; Sata, M; Torimura, T; Ueno, T; Yano, H | 1 |
| Alberts, SR; Dakhil, SR; Fitch, TR; Gross, HM; Kim, GP; Morlan, BW; Nair, S | 1 |
| Bertran, E; Caja, L; Campbell, JS; Fabregat, I; Fausto, N; Ortiz, C; Sancho, P | 1 |
| Erlichman, C; Flynn, PJ; Holen, KD; Mahoney, MR; Northfelt, DW; Philip, PA; Picus, J; Pitot, HC | 1 |
| Bodzin, AS; Doria, C; Gu, T; Hurtt, R; Wei, Z | 1 |
| Chen, CH; Hsu, WM; Hu, RH; Huang, HC; Huang, J; Huang, MC; Huang, MJ; Lai, HS; Lee, JJ; Lee, PH; Liu, CH; Wu, YM | 1 |
| Chen, L; Gu, J; Liu, H; Sun, L; Wang, S; Wen, Y; Xu, J; Yun, X; Zhou, L | 1 |
| Buck, E; Desai, V; Epstein, DM; Miglarese, M; Wang, J; Zhao, H | 1 |
| Bufill, JA; Chiorean, EG; Coleman, N; Currie, C; Johnston, EL; Loehrer, PJ; Picus, J; Ramasubbaiah, R; Tong, Y; Yu, M | 1 |
| Chao, Y; Cheng, AL; Hsieh, RK; Hsieh, TY; Hsu, C; Huang, WT; Huo, TI; Hwang, WS; Meng, R; Yang, TS; Yu, CW | 1 |
| Berger, W; Grasl-Kraupp, B; Grunt, T; Grusch, M; Holzmann, K; Koppensteiner, H; Krupitza, G; Lackner, A; Losert, A; Lötsch, D; Marian, B; Peter-Vörösmarty, B; Schmid, K; Schulte-Hermann, R; Steiner, E | 1 |
| Abbruzzese, JL; Deaton, FL; Garrett-Mayer, E; Hassabo, HM; Hassan, MM; Iwasaki, M; Kaseb, AO; Lin, E; Morris, JS; Onicescu, G; Thomas, MB; Xiao, L | 1 |
| Chan, P; Cheung, TT; Fan, ST; Pang, R; Poon, RT; Wong, H; Yao, TJ; Yau, T | 1 |
| Aoudjehane, L; Barbu, V; Blivet-Van Eggelpoël, MJ; Chettouh, H; Desbois-Mouthon, C; Fartoux, L; Housset, C; Priam, S; Rey, C; Rosmorduc, O | 1 |
| Dauser, B; Dienes, HP; Dufour, JF; Hayden, H; Peck-Radosavljevic, M; Piguet, AC; Pinter, M; Prager, G; Rohr-Udilova, N; Sieghart, W | 1 |
| Govindarajan, R; Makhoul, I; Siegel, E; Williamson, S | 1 |
| Abou-Alfa, GK; Ang, C; O'Reilly, EM | 1 |
| Aasrum, M; Christoffersen, T; Dajani, O; Guren, T; Müller, KM; Sandnes, D; Tveteraas, IH; Ødegård, J | 1 |
| Cserepes T, M; Döme, B; Rényi-Vámos, F; Török, S | 1 |
| Cai, X; Cao, P; Hu, C; Lu, W; Xu, X; Yang, J; Yu, Q | 1 |
| Arma, D; Balabaud, C; Bexiga, MG; Bioulac-Sage, P; Blanc, JF; Castain, C; Chevet, E; Higa, A; Le Bail, B; Marza, E; Rosenbaum, J; Simpson, JC; Taouji, S; Yi, P | 1 |
| Chang, YL; Chen, HJ; Chen, KF; Cheng, AL; Liu, CY; Shiau, CW; Yu, HC | 1 |
| Chang, AY; Wang, M | 1 |
| Abrams, TA; Ancukiewicz, M; Bhargava, P; Blaszkowsky, LS; Duda, DG; Fuchs, CS; Jain, RK; Knowles, M; McCleary, NJ; Meyerhardt, JA; Muzikansky, A; Regan, E; Ryan, DP; Sahani, DV; Sheehan, S; Supko, JG; Vasudev, E; Zhu, AX | 1 |
| Aguirre Ghiso, J; Estrada, Y; Liu, D; Ossowski, L | 1 |
| Matsuo, M; Saiki, I; Sakurai, H | 1 |
| Hao, LH; Li, X; Li, Y; Xu, JM; Yuan, SJ; Zhao, QC; Zhu, BD | 1 |
| Alper, R; Ilan, Y; Nagler, A; Ohana, M; Pines, M; Shapira, MY; Shibolet, O; Vlodavsky, I | 1 |
| Antonaci, S; Azzariti, A; Fransvea, E; Giannelli, G; Paradiso, A; Porcelli, L | 1 |
| Höpfner, M; Huether, A; Scherübl, H; Schuppan, D; Sutter, AP; Zeitz, M | 1 |
| Barbu, V; Cacheux, W; Clergue, F; Desbois-Mouthon, C; Housset, C; Poupon, R; Rey, C; Rosmorduc, O; Schiffer, E; Wendum, D | 1 |
| Li, X; Li, Y; Lu, QY; Yuan, SJ; Zhao, QC; Zhu, BD | 1 |
| Choo, MK; Koizumi, K; Matsuo, M; Saiki, I; Sakurai, H; Ueno, Y | 1 |
| Jeng, YM; Lien, HC; Su, MC | 1 |
| Höpfner, M; Huether, A; Scherübl, H; Schuppan, D; Sutter, AP | 1 |
| Allmer, C; Donehower, RC; Erlichman, C; Fitch, T; Kim, G; Mahoney, MR; Philip, PA; Picus, J; Pitot, HC; Thomas, J | 1 |
| Antonaci, S; Azzariti, A; Giannelli, G; Paradiso, A; Porcelli, L; Sgarra, C | 2 |
| Matsuo, M; Ohtani, O; Saiki, I; Sakurai, H; Ueno, Y | 1 |
| Greten, TF | 1 |
| Chen, IB; Chiu, HF; Huang, HS; Tao, CW | 1 |
| Bièche, I; Blanc, JF; Dugot-Senant, N; Laurendeau, I; Pines, M; Rosenbaum, J; Rullier, A; Taras, D | 1 |
| Avila, MA; Berasain, C; Castillo, J; Erroba, E; Lee, DC; Perugorría, MJ; Prieto, J; Santamaría, M | 1 |
| Chen, H; Fan, ST; Kok, TW; Liu, Y; Poon, RT; Shao, W; Sun, X | 1 |
| Baradari, V; Hopfner, M; Huether, A; Scherubl, H; Schuppan, D; Sutter, AP | 1 |
| Clendeninn, N; Dancey, J; Hamburg, S; Hochster, H; Jhawer, M; Mani, S; Rosen, L; Tempero, M | 1 |
| Barbu, V; Blivet-Van Eggelpoël, MJ; Cacheux, W; Desbois-Mouthon, C; Fartoux, L; Housset, C; Poupon, R; Rosmorduc, O | 1 |
| Antonaci, S; Giannelli, G | 1 |
| Desbois-Mouthon, C; Fartoux, L; Poupon, R; Rosmorduc, O | 1 |
| Abbruzzese, JL; Brown, T; Chadha, R; Dancey, J; Glover, K; Morris, J; Rashid, A; Thomas, MB; Wang, X | 1 |
| Croitoru, A; Feld, R; Feun, L; Gallo, J; Gish, RG; Jeziorski, K; Kennealey, GT; Lazar, L; Leighton, J; Porta, C; Ruff, P | 1 |
| Aasrum, M; Christoffersen, T; Dajani, OF; Guren, TK; Lilleby, P; Meisdalen, K; Sandnes, D; Thoresen, GH; Tveteraas, IH | 1 |
| Boeck, S; Heinemann, V; Wollenberg, A | 1 |
| Zhu, AX | 1 |
| O'Neil, BH; Venook, AP | 1 |
| Biagi, JJ; Cripps, C; Eisenhauer, E; Feld, R; Gill, S; Knox, JJ; Major, P; Seymour, L; Synold, TW; Wainman, N | 1 |
| Dorfman, JD; Fuchs, BC; Fujii, T; Goodwin, JM; Lanuti, M; Tanabe, KK; Zhu, AX | 1 |
| Adenis, A; Carr, BI; Ducreux, M; François, E; Kerr, D; Rougier, P; Seymour, L | 1 |
| Ciesla, J; Dzik, JM; Hardy, LW; Maley, F; Maley, GF; Montfort, WR; Rode, W; Sotelo-Mundo, RR | 1 |
| Clendennin, N; Johnston, A; Rudy, J; Stuart, K; Tessitore, J | 1 |
| Chak, K; Chan, AT; Chao, Y; Huang, A; Johnson, P; Johnston, A; Lee, SD; Leung, TW; Lui, MC; Mok, TS; Yeo, W | 1 |
| Dorko, K; Esplen, JE; Jo, M; Michalopoulos, GK; Stolz, DB; Strom, SC | 1 |
| Bader, H; Beardsley, GP; DeYarman, MT; Freisheim, JH; Galivan, J; Kerwar, SS; Moroson, BA; O'Connor, BM; Rosowsky, A; Russello, O | 1 |
| Balinska, M; Bunni, M; Galivan, J; Maley, F; Maley, GF; Priest, DG; Rhee, MS | 1 |
| Buamah, PK; Cornell, C; Harris, AL; James, OF; Skillen, AW | 1 |
| Buamah, PK; Harris, AL; James, OF; Skillen, AW | 1 |
| Bassendine, MF; Curtin, NJ; Harris, AL; James, OF; Loose, H | 1 |
| Bassendine, MF; Curtin, NJ; Harris, AL; James, OF | 1 |
| Bennett, M; Buamah, PK; James, OF; Lendrum, R; McArdle, P | 1 |
| Maley, F; Maley, GF | 1 |
8 review(s) available for quinazolines and Hepatocellular Carcinoma
| Article | Year |
|---|---|
Erlotinib.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Liver Neoplasms; Lung Neoplasms; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2014 |
Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carcinoma, Hepatocellular; Clinical Trials as Topic; Cytotoxins; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Neoplasm Proteins; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Purines; Quinazolines; RNA, Small Interfering; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
[New possibilities of targeted therapy in the treatment of hepatocellular carcinoma with the help of molecular biology].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Carcinoma, Hepatocellular; Catheter Ablation; Cell Cycle; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Epigenesis, Genetic; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Hepatectomy; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Wnt Proteins | 2010 |
Targeted agents and systemic therapy in hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Benzenesulfonates; Carcinoma, Hepatocellular; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunotherapy; Liver Neoplasms; Molecular Targeted Therapy; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib; Vascular Endothelial Growth Factor A | 2013 |
[Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects].
Topics: Animals; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Colorectal Neoplasms; Digestive System; Enzyme Inhibitors; Female; Genital Neoplasms, Female; Humans; Imidazoles; Indazoles; Indoles; Liver Neoplasms; Lung Neoplasms; Male; Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Quinazolines; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays | 2012 |
Novel concepts in hepatocellular carcinoma: from molecular research to clinical practice.
Topics: Antineoplastic Agents; beta Catenin; Carcinoma, Hepatocellular; Cell Differentiation; Cell Transformation, Neoplastic; ErbB Receptors; Gefitinib; Humans; Liver Cirrhosis; Neoplasm Invasiveness; Prognosis; Quinazolines | 2006 |
[Anti-EGFR therapy: towards a "à la carte" targeting of hepatocellular carcinoma].
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cetuximab; Clinical Trials, Phase II as Topic; Disease Models, Animal; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Ligands; Liver Neoplasms; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Rats; Signal Transduction; Transforming Growth Factor alpha | 2006 |
Hepatocellular carcinoma: the role of the North American GI Steering Committee Hepatobiliary Task Force and the advent of effective drug therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Erlotinib Hydrochloride; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib | 2007 |
24 trial(s) available for quinazolines and Hepatocellular Carcinoma
| Article | Year |
|---|---|
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Administration Schedule; Female; Fibroblast Growth Factors; Humans; Liver Neoplasms; Male; Middle Aged; Pyrans; Quinazolines; Receptor, Fibroblast Growth Factor, Type 4; Signal Transduction; Treatment Outcome; Young Adult | 2019 |
Hepatic arterial infusion of oxaliplatin plus raltitrexed in patients with intermediate and advanced stage hepatocellular carcinoma: A phase II, single-arm, prospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Oxaliplatin; Prognosis; Prospective Studies; Quinazolines; Survival Rate; Thiophenes | 2020 |
Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: a multicenter phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bevacizumab; Carcinoma, Hepatocellular; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Liver Neoplasms; Male; Middle Aged; Proto-Oncogene Proteins c-akt; Quinazolines; Treatment Outcome; Vascular Endothelial Growth Factor A | 2013 |
SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Double-Blind Method; Erlotinib Hydrochloride; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Placebos; Quinazolines; Sorafenib | 2015 |
Raltitrexed plus oxaliplatin-based transarterial chemoembolization in patients with unresectable hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Doxorubicin; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes; Young Adult | 2016 |
Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Hepatocellular; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Liver Neoplasms; Male; Middle Aged; Quinazolines; Vascular Endothelial Growth Factor A | 2009 |
A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer.
Topics: Antineoplastic Agents; Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Humans; Lapatinib; Liver Neoplasms; Quinazolines; Survival Analysis | 2009 |
A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Disease Progression; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lapatinib; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Predictive Value of Tests; Quinazolines; Survival Rate | 2009 |
Cediranib (AZD2171) in patients with advanced hepatocellular carcinoma: a phase II North Central Cancer Treatment Group Clinical Trial.
Topics: Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Grading; Prognosis; Quinazolines; Survival Rate | 2012 |
Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Hepatocellular; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Liver Neoplasms; Male; Middle Aged; Quinazolines; Treatment Outcome | 2012 |
Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cadherins; Carcinoma, Hepatocellular; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Liver Neoplasms; Male; Middle Aged; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Taxoids | 2012 |
Vandetanib in patients with inoperable hepatocellular carcinoma: a phase II, randomized, double-blind, placebo-controlled study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; ErbB Receptors; Female; Humans; Liver Neoplasms; Male; Middle Aged; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Survival Rate; Treatment Outcome | 2012 |
Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Angiopoietin-2; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Hepatocellular; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Liver Neoplasms; Male; Middle Aged; Proportional Hazards Models; Quinazolines | 2012 |
Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Quinazolines; Sorafenib | 2012 |
Bevacizumab and erlotinib in previously untreated inoperable and metastatic hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Hepatocellular; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Salvage Therapy; Survival Rate; Treatment Outcome | 2013 |
Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study.
Topics: Aged; Carcinoma, Hepatocellular; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Proteins; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor Receptor-1 | 2013 |
Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Probability; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Outcome | 2005 |
Phase II trial of nolatrexed dihydrochloride [Thymitaq, AG 337] in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Drug Administration Schedule; Exanthema; Female; Humans; Infusions, Intravenous; Liver Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Quinazolines; Stomatitis; Survival Analysis; Time Factors; Treatment Outcome | 2007 |
Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Diarrhea; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Fatigue; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2007 |
Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Palliative Care; Quality of Life; Quinazolines; Risk Assessment; Survival Analysis; Terminally Ill | 2007 |
A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168).
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Carcinoma, Hepatocellular; Disease Progression; Female; Gene Expression; Humans; Infusions, Intravenous; Kinesins; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Quinazolines; Treatment Outcome | 2008 |
A phase II study of raltitrexed ('Tomudex') in patients with hepatocellular carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Female; Folic Acid Antagonists; Humans; Liver Neoplasms; Male; Middle Aged; Quinazolines; Thiophenes | 1997 |
A Phase II trial of nolatrexed dihydrochloride in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Survival Analysis; Thymidylate Synthase | 1999 |
A multi-centre randomized phase II study of nolatrexed versus doxorubicin in treatment of Chinese patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Hepatocellular; Doxorubicin; Female; Humans; Infusions, Intravenous; Liver Neoplasms; Male; Middle Aged; Quinazolines; Survival Analysis | 1999 |
126 other study(ies) available for quinazolines and Hepatocellular Carcinoma
| Article | Year |
|---|---|
QNZ alleviated hepatocellular carcinoma by targeting inflammatory pathways in a rat model.
Topics: alpha-Fetoproteins; Animals; beta Catenin; Carcinoma, Hepatocellular; Disease Models, Animal; Glycogen Synthase Kinase 3; Hepatocytes; Inflammation; Liver; Liver Neoplasms; MAP Kinase Kinase Kinase 5; NF-kappa B; Organ Specificity; Phenyl Ethers; Quinazolines; Rats; Rats, Sprague-Dawley; Survival Analysis; TNF Receptor-Associated Factor 2; Tumor Necrosis Factor-alpha | 2021 |
A Critical YAP in Malignancy of HCC Is Regulated by Evodiamine.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Mitochondria; Quinazolines; Up-Regulation; YAP-Signaling Proteins | 2022 |
Design, synthesis, and biological evaluation of quinazoline derivatives with covalent reversible warheads as potential FGFR4 inhibitors.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Humans; Liver Neoplasms; Quinazolines; Receptor, Fibroblast Growth Factor, Type 4 | 2022 |
Phase 0 Study of Vandetanib-Eluting Radiopaque Embolics as a Preoperative Embolization Treatment in Patients with Resectable Liver Malignancies.
Topics: Adolescent; Adult; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Piperidines; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2022 |
Preliminary outcomes of raltitrexed eluting bead-transarterial chemoembolization using Callispheres® beads for gastrointestinal adenocarcinoma liver metastasis.
Topics: Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Gastrointestinal Neoplasms; Humans; Liver Neoplasms; Male; Microspheres; Middle Aged; Quinazolines; Retrospective Studies; Thiophenes; Treatment Outcome | 2022 |
Clinical Outcomes of Drug-Eluting Bead Transarterial Chemoembolization Loaded with Raltitrexed for the Treatment of Unresectable or Recurrent Hepatocellular Carcinoma.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Doxorubicin; Humans; Liver Neoplasms; Quinazolines; Retrospective Studies; Thiophenes; Treatment Outcome | 2022 |
G9a and histone deacetylases are crucial for Snail2-mediated E-cadherin repression and metastasis in hepatocellular carcinoma.
Topics: Acetylation; Animals; Azepines; Cadherins; Carcinoma, Hepatocellular; Cell Movement; Disease Progression; Down-Regulation; Epigenesis, Genetic; Epithelial-Mesenchymal Transition; Female; Histocompatibility Antigens; Histone Deacetylase Inhibitors; Histone Deacetylases; Histone-Lysine N-Methyltransferase; Humans; Hydroxamic Acids; Liver; Liver Neoplasms; Methylation; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Quinazolines; Snail Family Transcription Factors; Transcription, Genetic; Transforming Growth Factor beta | 2019 |
Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.
Topics: Aged, 80 and over; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Fibroblast Growth Factors; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Mice; Middle Aged; Models, Molecular; Mutation; Neoplasm Transplantation; Protein Domains; Pyrans; Quinazolines; Receptor, Fibroblast Growth Factor, Type 4 | 2019 |
Evolution of Transarterial Chemoembolization for the Treatment of Liver Cancer.
Topics: Animals; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Liver Neoplasms; Piperidines; Quinazolines; Rabbits | 2019 |
Nanodiamond-Mediated Delivery of a G9a Inhibitor for Hepatocellular Carcinoma Therapy.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; DNA Methylation; Drug Delivery Systems; Gene Expression Regulation, Neoplastic; Histocompatibility Antigens; Histone Code; Histone-Lysine N-Methyltransferase; Humans; Liver Neoplasms; Mice; Nanodiamonds; Quinazolines | 2019 |
Deubiquitinating enzyme USP10 promotes hepatocellular carcinoma metastasis through deubiquitinating and stabilizing Smad4 protein.
Topics: Animals; Benzylamines; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Binding; Protein Stability; Quinazolines; RNA, Small Interfering; Smad4 Protein; Transforming Growth Factor beta; Ubiquitin Thiolesterase; Ubiquitination; Xenograft Model Antitumor Assays | 2020 |
Oxaliplatin resistance is enhanced by saracatinib via upregulation Wnt-ABCG1 signaling in hepatocellular carcinoma.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 1; Benzodioxoles; Carcinoma, Hepatocellular; Cell Line, Tumor; Computational Biology; Disease Models, Animal; Drug Antagonism; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation; Humans; Liver Neoplasms; Mice; Oxaliplatin; Quinazolines; Signal Transduction; Wnt Proteins; Xenograft Model Antitumor Assays | 2020 |
Knockdown of otubain 2 inhibits liver cancer cell growth by suppressing NF-κB signaling.
Topics: Carcinogenesis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Gene Expression Regulation, Neoplastic; Genes, Reporter; Hepatoblastoma; Humans; Liver Neoplasms; Luciferases; Phenyl Ethers; Phenylenediamines; Phosphorylation; Quinazolines; RNA, Small Interfering; Signal Transduction; Survival Analysis; Thiolester Hydrolases; Transcription Factor RelA | 2020 |
Evodiamine inhibits proliferation and promotes apoptosis of hepatocellular carcinoma cells via the Hippo-Yes-Associated Protein signaling pathway.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Female; Hep G2 Cells; Hippo Signaling Pathway; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Serine-Threonine Kinases; Quinazolines; Signal Transduction; Transcription Factors; Xenograft Model Antitumor Assays; YAP-Signaling Proteins | 2020 |
A Case-Control Study on the Correlation Between Thymidylate Synthase Gene Polymorphisms and Raltitrexed Treatment Combined with Transcatheter Arterial Chemoembolization in Hepatocellular Carcinoma Treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Carcinoma, Hepatocellular; Case-Control Studies; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Quinazolines; Survival Rate; Thiophenes; Thymidylate Synthase; Treatment Outcome | 2020 |
Fibroblast Growth Factor 9 is expressed by activated hepatic stellate cells and promotes progression of hepatocellular carcinoma.
Topics: Acrylamides; Apoptosis; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Fibroblast Growth Factor 9; Gene Expression Regulation, Neoplastic; Hepatic Stellate Cells; Humans; Liver Neoplasms; Prognosis; Quinazolines; Receptor, Fibroblast Growth Factor, Type 4; Survival Rate; Tumor Cells, Cultured | 2020 |
CCL22 signaling contributes to sorafenib resistance in hepatitis B virus-associated hepatocellular carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemokine CCL22; Drug Resistance, Neoplasm; Hep G2 Cells; Hepatitis B; Humans; Liver Neoplasms; Lymphocytes, Tumor-Infiltrating; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Protein Kinase Inhibitors; Quinazolines; Receptors, CCR4; Signal Transduction; Sorafenib; T-Lymphocytes; Tumor Burden | 2020 |
Euchromatin histone methyltransferase II (EHMT2) regulates the expression of ras-related GTP binding C (RRAGC) protein.
Topics: Apoptosis; Azepines; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Chromatin Immunoprecipitation; Euchromatin; Gene Expression; Gene Expression Regulation; Histocompatibility Antigens; Histone Methyltransferases; Histone-Lysine N-Methyltransferase; Histones; Humans; Liver Neoplasms; Monomeric GTP-Binding Proteins; Proteomics; Quinazolines; Reactive Oxygen Species; Stress, Physiological; Transcriptome | 2020 |
The quinazoline derivative, 04NB-03, induces cell cycle arrest and apoptosis in hepatocellular carcinoma cells in a reactive oxygen species-dependent manner.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Female; G2 Phase Cell Cycle Checkpoints; Humans; Inhibitory Concentration 50; Liver Neoplasms; M Phase Cell Cycle Checkpoints; Mice, Inbred BALB C; Mice, Nude; Quinazolines; Reactive Oxygen Species | 2021 |
Vandetanib-eluting radiopaque beads for chemoembolization: physicochemical evaluation and biological activity of vandetanib in hypoxia.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Chemoembolization, Therapeutic; Drug Liberation; Human Umbilical Vein Endothelial Cells; Humans; Hypoxia; Liver Neoplasms; MAP Kinase Signaling System; Neovascularization, Pathologic; Piperidines; Quinazolines; Vascular Endothelial Growth Factors | 2021 |
HER3 PET Imaging Identifies Dynamic Changes in HER3 in Response to HER2 Inhibition with Lapatinib.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Liver Neoplasms; Mice; Positron-Emission Tomography; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Tissue Distribution | 2021 |
Design, synthesis and bioactivity study of evodiamine derivatives as multifunctional agents for the treatment of hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Male; Mice; Mice, Nude; Molecular Structure; Quinazolines; Structure-Activity Relationship; Tumor Cells, Cultured | 2021 |
Histone lysine methyltransferase G9a is a novel epigenetic target for the treatment of hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Animals; Azepines; Blotting, Western; Carcinoma, Hepatocellular; Chromatin Immunoprecipitation; DNA Methylation; Enzyme Inhibitors; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Histocompatibility Antigens; Histone-Lysine N-Methyltransferase; Histones; Humans; Immunohistochemistry; Liver Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Quinazolines; Real-Time Polymerase Chain Reaction; Xenograft Model Antitumor Assays | 2017 |
Topics: Antineoplastic Agents; Benzenesulfonates; Carbon-13 Magnetic Resonance Spectroscopy; Carcinoma, Hepatocellular; Cell Proliferation; Chromatography, Liquid; Dose-Response Relationship, Drug; Drug Design; Hep G2 Cells; Humans; Liver Neoplasms; Mass Spectrometry; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Structure; Proton Magnetic Resonance Spectroscopy; Pyrimidines; Quinazolines; Spectroscopy, Fourier Transform Infrared; Structure-Activity Relationship | 2017 |
Evodiamine Exerts an Anti-Hepatocellular Carcinoma Activity through a WWOX-Dependent Pathway.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; beta Catenin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Evodia; Gene Knockdown Techniques; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred C57BL; Plant Extracts; Quinazolines; WW Domain-Containing Oxidoreductase | 2017 |
HZ-6d targeted HERC5 to regulate p53 ISGylation in human hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzofurans; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Delivery Systems; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Quinazolines; Tumor Suppressor Protein p53 | 2017 |
Implications of FGF19 on sorafenib-mediated nitric oxide production in hepatocellular carcinoma cells - a short report.
Topics: Acrylamides; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Fibroblast Growth Factors; Hep G2 Cells; Humans; Liver Neoplasms; Niacinamide; Nitric Oxide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinazolines; Receptor, Fibroblast Growth Factor, Type 4; Sorafenib | 2018 |
Inhibition of CUG-binding protein 1 and activation of caspases are critically involved in piperazine derivative BK10007S induced apoptosis in hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Caspases; CELF1 Protein; Cell Proliferation; Enzyme Activation; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Piperazines; Quinazolines | 2017 |
Evodiamine induces apoptosis and promotes hepatocellular carcinoma cell death induced by vorinostat via downregulating HIF-1α under hypoxia.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Synergism; Humans; Hydroxamic Acids; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Quinazolines; Vorinostat | 2018 |
Antagonizing SET Augments the Effects of Radiation Therapy in Hepatocellular Carcinoma through Reactivation of PP2A-Mediated Akt Downregulation.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; DNA-Binding Proteins; Down-Regulation; Enzyme Activation; Histone Chaperones; Humans; Liver Neoplasms; Male; Mice; Protein Phosphatase 2; Proto-Oncogene Proteins c-akt; Quinazolines; Transcription Factors; Xenograft Model Antitumor Assays | 2018 |
Transarterial embolization and low-dose continuous hepatic arterial infusion chemotherapy with oxaliplatin and raltitrexed for hepatocellular carcinoma with major portal vein tumor thrombus.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Catheters; Chemoembolization, Therapeutic; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Portal Vein; Quinazolines; Retrospective Studies; Survival Rate; Thiophenes; Thrombosis; Treatment Outcome | 2018 |
Evodiamine Induces Apoptosis in SMMC-7721 and HepG2 Cells by Suppressing NOD1 Signal Pathway.
Topics: Animals; Carcinoma, Hepatocellular; Hep G2 Cells; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Nod1 Signaling Adaptor Protein; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2018 |
AZD3759 induces apoptosis in hepatoma cells by activating a p53-SMAD4 positive feedback loop.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Piperazines; Quinazolines; Signal Transduction; Smad4 Protein; Tumor Suppressor Protein p53 | 2019 |
A concise synthesis and biological study of evodiamine and its analogues.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Chemistry Techniques, Synthetic; Evodia; Humans; Liver Neoplasms; Quinazolines | 2019 |
Down-regulation of Survivin by BIX-01294 Pretreatment Overcomes Resistance of Hepatocellular Carcinoma Cells to TRAIL.
Topics: Azepines; Carcinoma, Hepatocellular; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Quinazolines; Survivin; TNF-Related Apoptosis-Inducing Ligand | 2019 |
Growth inhibitor of human hepatic carcinoma HepG2 cells by evodiamine is associated with downregulation of PRAME.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Hepatocellular; Cell Survival; Down-Regulation; Hep G2 Cells; Humans; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Quinazolines; RNA, Messenger | 2019 |
Epidermal growth factor receptor signaling impairs the antiviral activity of interferon-alpha.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cell Line; Cells, Cultured; Drug Synergism; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Hepacivirus; Hepatitis C; Hepatocytes; Humans; Interferon-alpha; Liver Neoplasms; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; STAT3 Transcription Factor; Suppressor of Cytokine Signaling 3 Protein; Suppressor of Cytokine Signaling Proteins; Treatment Outcome | 2013 |
Cutaneous leukocytoclastic vasculitis due to erlotinib: just an adverse event or also a putative marker of drug efficacy?
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Erlotinib Hydrochloride; Humans; Liver Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; Vasculitis, Leukocytoclastic, Cutaneous | 2013 |
Synthesis, tautomeric structures, and antitumor activity of new perimidines.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Hepatocellular; Female; Hep G2 Cells; Humans; Liver Neoplasms; MCF-7 Cells; Quinazolines; Spectrum Analysis | 2013 |
BCRP/ABCG2 inhibition sensitizes hepatocellular carcinoma cells to sorafenib.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport, Active; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Gefitinib; Hep G2 Cells; Humans; Liver Neoplasms; MAP Kinase Signaling System; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinazolines; RNA, Small Interfering; Sorafenib | 2013 |
Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.
Topics: Animals; Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Phenylurea Compounds; Quinazolines; Signal Transduction; Sorafenib; Transforming Growth Factor alpha; Up-Regulation | 2014 |
Caffeine and the analog CGS 15943 inhibit cancer cell growth by targeting the phosphoinositide 3-kinase/Akt pathway.
Topics: Antineoplastic Agents; Apoptosis; Caffeine; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Humans; Liver Neoplasms; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Purinergic P1 Receptor Agonists; Quinazolines; Signal Transduction; Triazoles | 2014 |
In-depth analysis shows synergy between erlotinib and miR-34a.
Topics: Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Erlotinib Hydrochloride; Humans; Liver Neoplasms; Lung Neoplasms; MicroRNAs; Quinazolines | 2014 |
Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma.
Topics: Animals; Bile Ducts; Carbon Tetrachloride; Carcinoma, Hepatocellular; Cell Proliferation; Cells, Cultured; Diethylnitrosamine; Disease Models, Animal; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Hepatic Stellate Cells; Hepatocytes; Humans; Ligation; Liver Cirrhosis; Liver Neoplasms; Male; Mice; Mice, Inbred Strains; Phosphorylation; Prognosis; Quinazolines; Rats; Rats, Wistar; Transcriptome | 2014 |
Erlotinib might be a double-edged sword in HCC.
Topics: Animals; Carcinoma, Hepatocellular; Disease Progression; ErbB Receptors; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Quinazolines | 2015 |
Reply: To PMID 24677197.
Topics: Animals; Carcinoma, Hepatocellular; Disease Progression; ErbB Receptors; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Quinazolines | 2015 |
Entrapment of an EGFR inhibitor into nanostructured lipid carriers (NLC) improves its antitumor activity against human hepatocarcinoma cells.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Carriers; ErbB Receptors; Humans; Lipids; Liver; Liver Neoplasms; Nanostructures; Quinazolines; Tyrphostins | 2014 |
Lapatinib induces autophagic cell death and inhibits growth of human hepatocellular carcinoma.
Topics: Animals; Apoptosis Regulatory Proteins; Autophagy; Autophagy-Related Protein 5; Autophagy-Related Protein 7; Beclin-1; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Hep G2 Cells; Humans; Immunoblotting; Lapatinib; Liver Neoplasms; Membrane Proteins; Mice, Inbred BALB C; Mice, Nude; Microscopy, Electron, Transmission; Microtubule-Associated Proteins; Mitochondria; Protein Kinase Inhibitors; Quinazolines; RNA Interference; Tumor Burden; Ubiquitin-Activating Enzymes; Xenograft Model Antitumor Assays | 2014 |
Erlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autoantigens; Carcinoma, Hepatocellular; Cell Line, Tumor; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Male; Membrane Proteins; Mice; Mice, Nude; Protein Phosphatase 2; Proto-Oncogene Proteins c-akt; Quinazolines; Xenograft Model Antitumor Assays | 2014 |
Reactive oxygen species-mediated activation of the Src-epidermal growth factor receptor-Akt signaling cascade prevents bortezomib-induced apoptosis in hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Liver Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrazines; Quinazolines; Reactive Oxygen Species; Signal Transduction; src-Family Kinases | 2015 |
Des-gamma-carboxy prothrombin (DCP) antagonizes the effects of gefitinib on human hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers; Carcinoma, Hepatocellular; Caspases; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Gefitinib; Hep G2 Cells; Hepatocyte Growth Factor; Humans; Liver Neoplasms; Protein Precursors; Prothrombin; Proto-Oncogene Proteins c-met; Quinazolines; Up-Regulation | 2015 |
Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Silybin; Silymarin; Sorafenib | 2015 |
Modulation of Regorafenib effects on HCC cell lines by epidermal growth factor.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Epidermal Growth Factor; Erlotinib Hydrochloride; Hep G2 Cells; Humans; Liver Neoplasms; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Phosphorylation; Pyridines; Quinazolines; Sorafenib | 2015 |
The Histone Methyltransferase Inhibitor BIX01294 Inhibits HIF-1α Stability and Angiogenesis.
Topics: Animals; Azepines; Carcinoma, Hepatocellular; Chick Embryo; Enzyme Inhibitors; Hep G2 Cells; Histone Methyltransferases; Histone-Lysine N-Methyltransferase; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Mice; Neovascularization, Pathologic; Quinazolines; Signal Transduction | 2015 |
HBx sensitizes hepatocellular carcinoma cells to lapatinib by up-regulating ErbB3.
Topics: Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Survival; ErbB Receptors; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Hepatitis B virus; Humans; Lapatinib; Liver Neoplasms; NF-kappa B; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Trans-Activators; Up-Regulation; Viral Regulatory and Accessory Proteins | 2016 |
Gefitinib Synergizes with Irinotecan to Suppress Hepatocellular Carcinoma via Antagonizing Rad51-Mediated DNA-Repair.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Camptothecin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; DNA Repair; Drug Resistance, Neoplasm; Drug Synergism; Gefitinib; Hep G2 Cells; Humans; Irinotecan; Liver Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Quinazolines; Rad51 Recombinase; RNA, Small Interfering; Topoisomerase I Inhibitors | 2016 |
Upregulation of the oncoprotein SET determines poor clinical outcomes in hepatocellular carcinoma and shows therapeutic potential.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; DNA-Binding Proteins; Female; Gene Expression Regulation, Neoplastic; Histone Chaperones; Humans; Liver Neoplasms; Male; Mice; Niacinamide; Phenylurea Compounds; Prognosis; Quinazolines; Sorafenib; Transcription Factors; Xenograft Model Antitumor Assays | 2016 |
Raltitrexed Inhibits HepG2 Cell Proliferation via G0/G1 Cell Cycle Arrest.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Proliferation; Cyclin A; Cyclin-Dependent Kinase 2; G1 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; Genes, p16; Genes, p53; Hep G2 Cells; Humans; Liver Neoplasms; Quinazolines; Resting Phase, Cell Cycle; S Phase; Thiophenes | 2016 |
iRGD-Decorated Polymeric Nanoparticles for the Efficient Delivery of Vandetanib to Hepatocellular Carcinoma: Preparation and in Vitro and in Vivo Evaluation.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Drug Delivery Systems; Liver Neoplasms; Mice; Nanoparticles; Piperidines; Polymers; Quinazolines | 2016 |
Evodiamine exerts anti-tumor effects against hepatocellular carcinoma through inhibiting β-catenin-mediated angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; beta Catenin; Blotting, Western; Carcinoma, Hepatocellular; Cell Line; Cell Line, Tumor; Cell Movement; Cell Survival; Evodia; Hep G2 Cells; Humans; Immunohistochemistry; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Phytotherapy; Plant Extracts; Quinazolines; Rats, Sprague-Dawley; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2016 |
Effect of saracatinib on pulmonary metastases from hepatocellular carcinoma.
Topics: Animals; Benzodioxoles; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Humans; Liver Neoplasms; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Phosphorylation; Quinazolines; Signal Transduction; src-Family Kinases; Xenograft Model Antitumor Assays | 2016 |
Regorafenib induces extrinsic and intrinsic apoptosis through inhibition of ERK/NF-κB activation in hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Humans; Liver Neoplasms; Membrane Potential, Mitochondrial; NF-kappa B; Phenyl Ethers; Phenylurea Compounds; Phosphorylation; Pyridines; Quinazolines; X-Linked Inhibitor of Apoptosis Protein | 2017 |
Choline Kinase α Mediates Interactions Between the Epidermal Growth Factor Receptor and Mechanistic Target of Rapamycin Complex 2 in Hepatocellular Carcinoma Cells to Promote Drug Resistance and Xenograft Tumor Progression.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line; Cell Line, Tumor; Cell Movement; Choline Kinase; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Hep G2 Cells; Humans; Immunoblotting; Immunohistochemistry; Liver Neoplasms; Mechanistic Target of Rapamycin Complex 2; Mice; Multiprotein Complexes; Neoplasm Invasiveness; Neoplasm Transplantation; Quinazolines; RNA, Messenger; TOR Serine-Threonine Kinases; Wound Healing; Xenograft Model Antitumor Assays | 2017 |
Preparation and characterisation of vandetanib-eluting radiopaque beads for locoregional treatment of hepatic malignancies.
Topics: Carcinoma, Hepatocellular; Contrast Media; Drug Carriers; ErbB Receptors; Humans; Liver Neoplasms; Microspheres; Piperidines; Quinazolines; Vascular Endothelial Growth Factor A | 2017 |
Anti-tumor effect of evodiamine by inducing Akt-mediated apoptosis in hepatocellular carcinoma.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Evodia; Hep G2 Cells; Humans; Liver; Liver Neoplasms; Proto-Oncogene Proteins c-akt; Quinazolines | 2017 |
Exploration of anti-cancer effects and mechanisms of Zuo-Jin-Wan and its alkaloid components in vitro and in orthotopic HepG2 xenograft immunocompetent mice.
Topics: Alkaloids; Animals; Antineoplastic Agents, Phytogenic; Berberine; Carcinoma, Hepatocellular; Coptis; Drugs, Chinese Herbal; Evodia; Female; Hep G2 Cells; Heterografts; Humans; Medicine, Chinese Traditional; Mice, Inbred ICR; Phytotherapy; Quinazolines | 2017 |
Enhancement of apoptosis of human hepatocellular carcinoma SMMC-7721 cells through synergy of berberine and evodiamine.
Topics: Apoptosis; Berberine; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Drug Synergism; Humans; Liver Neoplasms; Phytotherapy; Plant Extracts; Quinazolines; Tumor Necrosis Factor-alpha | 2008 |
The inhibition of the epidermal growth factor (EGF) pathway enhances TGF-beta-induced apoptosis in rat hepatoma cells through inducing oxidative stress coincident with a change in the expression pattern of the NADPH oxidases (NOX) isoforms.
Topics: Animals; Antioxidants; Apoptosis; Carcinoma, Hepatocellular; Epidermal Growth Factor; ErbB Receptors; Gene Expression Regulation, Neoplastic; Isoenzymes; Liver Neoplasms; Mitochondria; NADH, NADPH Oxidoreductases; NADPH Oxidase 1; NADPH Oxidase 4; NADPH Oxidases; Oxidative Stress; Protein Kinase Inhibitors; Quinazolines; Rats; Reactive Oxygen Species; RNA, Small Interfering; Transforming Growth Factor beta; Tyrphostins | 2009 |
Long-term treatment of advanced hepatocellular carcinoma with the tyrosine kinase inhibitor erlotinib (Tarceva)--a case report.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Eruptions; Erlotinib Hydrochloride; Fatal Outcome; Follow-Up Studies; Humans; Liver Cirrhosis, Alcoholic; Liver Function Tests; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Palliative Care; Quinazolines; Ultrasonography | 2009 |
Severe photosensitivity reaction to vandetanib.
Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Middle Aged; Photosensitivity Disorders; Piperidines; Protein Kinase Inhibitors; Quinazolines | 2009 |
Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Insulin; Liver Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-3; Receptor, IGF Type 1; RNA, Small Interfering; Signal Transduction; Sirolimus | 2009 |
The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma.
Topics: Animals; Aurora Kinase B; Aurora Kinases; Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Female; Histones; Humans; Liver Neoplasms; Mice; Mice, Nude; Organophosphates; Phosphorylation; Protein Serine-Threonine Kinases; Quinazolines; Treatment Outcome; Xenograft Model Antitumor Assays | 2010 |
Gefitinib as an effective therapy for advanced hepatocellular carcinoma with lung metastasis?
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; ErbB Receptors; Female; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Gastrin-releasing peptide promotes the growth of HepG2 cells via EGFR-independent ERK1/2 activation.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Cells, Cultured; Enzyme Activation; ErbB Receptors; Gastrin-Releasing Peptide; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Indoles; Liver Neoplasms; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Quinazolines; Receptors, Bombesin | 2010 |
The transforming growth factor-beta (TGF-β) mediates acquisition of a mesenchymal stem cell-like phenotype in human liver cells.
Topics: Antigens, CD; Apoptosis; Apoptosis Regulatory Proteins; Cadherins; Carcinoma, Hepatocellular; Cell Proliferation; Cell Transdifferentiation; Cells, Cultured; ErbB Receptors; Gefitinib; Gene Expression Regulation; Hepatocytes; Humans; Liver; Liver Neoplasms; Mesenchymal Stem Cells; Neoplasm Invasiveness; Phenotype; Protein Kinase Inhibitors; Quinazolines; Recombinant Proteins; Signal Transduction; Snail Family Transcription Factors; Transcription Factors; Transforming Growth Factor beta1 | 2011 |
Could HBx protein expression affect signal pathway inhibition by gefitinib or selumetinib, a MEK inhibitor, in hepatocellular carcinoma cell lines?
Topics: Animals; Antineoplastic Agents; Benzimidazoles; beta Catenin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Humans; Liver Neoplasms; Mitogen-Activated Protein Kinase Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Trans-Activators; Viral Regulatory and Accessory Proteins | 2011 |
Inhibitory effects of Zuo-Jin-Wan and its alkaloidal ingredients on activator protein 1, nuclear factor-κB, and cellular transformation in HepG2 cells.
Topics: Antineoplastic Agents, Phytogenic; Berberine; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; Coptis; Drugs, Chinese Herbal; Evodia; Hep G2 Cells; Humans; Liver Neoplasms; NF-kappa B; Plant Extracts; Quinazolines; Tetradecanoylphorbol Acetate; Transcription Factor AP-1 | 2011 |
Metronomic S-1 chemotherapy and vandetanib: an efficacious and nontoxic treatment for hepatocellular carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Drug Combinations; ErbB Receptors; Fluorouracil; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Maximum Tolerated Dose; Mice; Mice, Inbred BALB C; Mice, Nude; Oxonic Acid; Piperidines; Quinazolines; Tegafur; Tumor Cells, Cultured | 2011 |
The tyrphostin AG1478 inhibits proliferation and induces death of liver tumor cells through EGF receptor-dependent and independent mechanisms.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Drug Synergism; ErbB Receptors; Fetus; Gene Knockdown Techniques; Hepatocytes; Humans; Liver Neoplasms; Quinazolines; Tyrphostins | 2011 |
Gefitinib resistance in HCC mahlavu cells: upregulation of CD133 expression, activation of IGF-1R signaling pathway, and enhancement of IGF-1R nuclear translocation.
Topics: AC133 Antigen; Active Transport, Cell Nucleus; Antigens, CD; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Nucleus; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Glycoproteins; Humans; Liver Neoplasms; Neoplastic Stem Cells; Peptides; Phosphorylation; Protein Transport; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, IGF Type 1; Signal Transduction; Up-Regulation | 2012 |
Mucin glycosylating enzyme GALNT2 regulates the malignant character of hepatocellular carcinoma by modifying the EGF receptor.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Down-Regulation; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Knockdown Techniques; Glycosylation; Hep G2 Cells; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mucins; N-Acetylgalactosaminyltransferases; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Polypeptide N-acetylgalactosaminyltransferase; Quinazolines; RNA, Messenger | 2011 |
Hepatitis B virus large surface antigen promotes liver carcinogenesis by activating the Src/PI3K/Akt pathway.
Topics: Aged; Aged, 80 and over; Animals; Benzodioxoles; Carcinoma, Hepatocellular; Cell Line; Cell Line, Tumor; Chlorocebus aethiops; Female; Hepatitis B Surface Antigens; Humans; Liver Neoplasms; Male; Mice; Mice, Nude; Middle Aged; Phosphatidylinositol 3-Kinases; Protein Kinase C-alpha; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-raf; Proto-Oncogene Proteins pp60(c-src); Quinazolines; RNA Interference; Signal Transduction; Vero Cells; Xenograft Model Antitumor Assays | 2011 |
Epithelial-mesenchymal transition predicts sensitivity to the dual IGF-1R/IR inhibitor OSI-906 in hepatocellular carcinoma cell lines.
Topics: Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Synergism; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Imidazoles; Insulin-Like Growth Factor II; Liver Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Quinazolines; Receptor, IGF Type 1; Receptor, Insulin; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction | 2012 |
The major vault protein mediates resistance to epidermal growth factor receptor inhibition in human hepatoma cells.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cytokines; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Liver Neoplasms; Protein Kinase Inhibitors; Quinazolines; RNA, Small Interfering; Signal Transduction; Vault Ribonucleoprotein Particles | 2012 |
Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells.
Topics: Adult; Aged; Aged, 80 and over; Amphiregulin; Animals; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Division; Drug Resistance, Neoplasm; EGF Family of Proteins; ErbB Receptors; Female; Gefitinib; Glycoproteins; Hep G2 Cells; Humans; Intercellular Signaling Peptides and Proteins; Liver Neoplasms, Experimental; Male; MAP Kinase Signaling System; Mice; Mice, Nude; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Receptor, ErbB-3; Sorafenib; Xenograft Model Antitumor Assays | 2012 |
Erlotinib and sorafenib in an orthotopic rat model of hepatocellular carcinoma.
Topics: Animals; Apoptosis; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Movement; Cell Survival; Drug Therapy, Combination; Endothelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Hep G2 Cells; Humans; Liver Neoplasms; Neoplasm Transplantation; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Rats; RNA, Messenger; Sorafenib; Vascular Endothelial Growth Factor A | 2012 |
Mechanisms involved in PGE2-induced transactivation of the epidermal growth factor receptor in MH1C1 hepatocarcinoma cells.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Dinoprostone; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Hepatocytes; Humans; Liver Neoplasms; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Rats; Signal Transduction | 2012 |
Evodiamine inhibits STAT3 signaling by inducing phosphatase shatterproof 1 in hepatocellular carcinoma cells.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Enzyme Activation; Female; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Interleukin-6; Janus Kinase 2; Liver Neoplasms; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Quinazolines; RNA Interference; Signal Transduction; src-Family Kinases; STAT3 Transcription Factor; Tyrphostins; Xenograft Model Antitumor Assays | 2013 |
Sorafenib-mediated targeting of the AAA⁺ ATPase p97/VCP leads to disruption of the secretory pathway, endoplasmic reticulum stress, and hepatocellular cancer cell death.
Topics: Adenosine Triphosphatases; Antineoplastic Agents; Apoptosis; Autophagy; Carcinoma, Hepatocellular; Cell Line, Tumor; Endoplasmic Reticulum Stress; Hep G2 Cells; Humans; Liver Neoplasms; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Secretory Pathway; Sorafenib | 2012 |
Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma.
Topics: Animals; Apoptosis; Autoantigens; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Down-Regulation; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Male; Membrane Proteins; Mice; Mice, Nude; Neoplasms, Experimental; Protein Kinase Inhibitors; Protein Phosphatase 2; Proto-Oncogene Proteins c-akt; Quinazolines; RNA, Small Interfering | 2013 |
In-vitro growth inhibition of chemotherapy and molecular targeted agents in hepatocellular carcinoma.
Topics: Alanine; alpha-Fetoproteins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Hepatocellular; Cetuximab; Dasatinib; Doxorubicin; Drug Screening Assays, Antitumor; Epothilones; Gefitinib; Humans; Indoles; Inhibitory Concentration 50; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Pyridones; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; Triazines | 2013 |
EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma.
Topics: Blotting, Northern; Carcinoma, Hepatocellular; Cell Division; Enzyme Activation; Enzyme Inhibitors; ErbB Receptors; Focal Adhesion Kinase 1; Focal Adhesion Protein-Tyrosine Kinases; Humans; Integrin beta1; Liver Neoplasms; Mitogen-Activated Protein Kinases; Protein Tyrosine Phosphatases; Protein-Tyrosine Kinases; Quinazolines; Receptors, Cell Surface; Receptors, Fibronectin; Receptors, Urokinase Plasminogen Activator; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Tumor Cells, Cultured; Tyrphostins | 2002 |
ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, shows antimetastatic activity using a hepatocellular carcinoma model.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Hepatocellular; Cell Division; Cell Line, Tumor; Cell Movement; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gefitinib; Liver Neoplasms; Mice; Neoplasm Metastasis; Neoplasm Transplantation; Phosphorylation; Quinazolines; Signal Transduction | 2003 |
[The effect of IRESSA on H22 mouse hepatocellular carcinoma].
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cisplatin; Disease Models, Animal; Gefitinib; Liver Neoplasms; Mice; Quinazolines; Random Allocation; Treatment Outcome | 2004 |
Suppression of hepatocellular carcinoma growth in mice by the alkaloid coccidiostat halofuginone.
Topics: alpha-Fetoproteins; Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Coccidiostats; Drug Screening Assays, Antitumor; Humans; Interferon-gamma; Interleukin-2; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Piperidines; Quinazolines; Quinazolinones | 2004 |
Laminin-5 offsets the efficacy of gefitinib ('Iressa') in hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Adhesion Molecules; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Kalinin; Phosphorylation; Predictive Value of Tests; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines | 2004 |
Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma.
Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Carcinoma, Hepatocellular; Cell Cycle; Cell Division; Cell Line, Tumor; Dose-Response Relationship, Drug; Down-Regulation; Drug Administration Schedule; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Humans; Liver Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Receptors, Somatomedin; RNA, Messenger | 2004 |
Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis.
Topics: Alkylating Agents; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Diethylnitrosamine; ErbB Receptors; Gefitinib; Liver Cirrhosis; Liver Neoplasms; Male; Quinazolines; Rats; Rats, Wistar; Signal Transduction; Transforming Growth Factor alpha | 2005 |
Antitumor effect of Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, combined with cytotoxic agent on murine hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Blood Cell Count; Body Weight; Carcinoma, Hepatocellular; Cisplatin; Cytotoxins; Drug Therapy, Combination; ErbB Receptors; Female; Gefitinib; Liver Neoplasms; Mice; Mice, Inbred Strains; Neoplasm Transplantation; Organ Size; Quinazolines; Spleen; Thymus Gland | 2005 |
Selective inhibition of TNF-alpha-induced activation of mitogen-activated protein kinases and metastatic activities by gefitinib.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Epidermal Growth Factor; Female; Gefitinib; MAP Kinase Signaling System; Mice; Mitogen-Activated Protein Kinases; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Tumor Necrosis Factor-alpha | 2005 |
Absence of epidermal growth factor receptor exon 18-21 mutation in hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Base Sequence; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Exons; Female; Gefitinib; Humans; Liver Neoplasms; Male; Middle Aged; Molecular Sequence Data; Point Mutation; Quinazolines; Sequence Analysis, DNA | 2005 |
Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Division; Cell Line, Tumor; Doxorubicin; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Humans; Liver Neoplasms; Quinazolines | 2005 |
ZD6474 inhibits proliferation and invasion of human hepatocellular carcinoma cells.
Topics: Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Adhesion; Cell Adhesion Molecules; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Extracellular Matrix Proteins; Humans; Immunoprecipitation; Inhibitory Concentration 50; Kalinin; Liver Neoplasms; Neoplasm Invasiveness; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Time Factors | 2006 |
Activation of MEK/ERK and PI3K/Akt pathways by fibronectin requires integrin alphav-mediated ADAM activity in hepatocellular carcinoma: a novel functional target for gefitinib.
Topics: ADAM Proteins; Animals; Carcinoma, Hepatocellular; Drug Therapy, Combination; ErbB Receptors; Fibronectins; Gefitinib; Integrin alphaV; Liver Neoplasms; MAP Kinase Kinase Kinases; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction | 2006 |
[Molecular therapy for HCC?].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Clinical Trials as Topic; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Probability; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Outcome | 2006 |
Synthesis and antitumor evaluation of symmetrical 1,5-diamidoanthraquinone derivatives as compared to their disubstituted homologues.
Topics: Anthraquinones; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Doxorubicin; Drug Screening Assays, Antitumor; Humans; Intercalating Agents; Mitoxantrone; Quinazolines; Structure-Activity Relationship | 2006 |
Halofuginone suppresses the lung metastasis of chemically induced hepatocellular carcinoma in rats through MMP inhibition.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Liver Neoplasms; Lung Neoplasms; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Matrix Metalloproteinases, Membrane-Associated; Neoplasm Metastasis; Piperidines; Quinazolines; Quinazolinones; Rats; Rats, Inbred F344 | 2006 |
Amphiregulin contributes to the transformed phenotype of human hepatocellular carcinoma cells.
Topics: Aged; Amphiregulin; Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Growth Processes; Cell Line, Tumor; Cell Transformation, Neoplastic; EGF Family of Proteins; ErbB Receptors; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Quinazolines; RNA, Small Interfering; Signal Transduction; Up-Regulation | 2006 |
Blockage of epidermal growth factor receptor by quinazoline tyrosine kinase inhibitors suppresses growth of human hepatocellular carcinoma.
Topics: Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Flow Cytometry; Humans; Liver Neoplasms; Mitogen-Activated Protein Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines | 2007 |
Signaling pathways involved in the inhibition of epidermal growth factor receptor by erlotinib in hepatocellular cancer.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; DNA, Complementary; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Humans; Insulin-Like Growth Factor I; Liver Neoplasms; Poly A; Protein Kinase Inhibitors; Quinazolines | 2006 |
Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Proliferation; ErbB Receptors; Flow Cytometry; Gefitinib; Humans; Insulin-Like Growth Factor II; Liver Neoplasms; Quinazolines; Receptor Cross-Talk; Receptor, IGF Type 1; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction | 2006 |
Prostaglandin E2 upregulates EGF-stimulated signaling in mitogenic pathways involving Akt and ERK in hepatocytes.
Topics: Animals; Carcinoma, Hepatocellular; Cell Culture Techniques; Cells, Cultured; Culture Media, Serum-Free; Cyclin D; Cyclins; Dinoprostone; DNA; Enzyme Activation; Epidermal Growth Factor; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Expression Regulation; Hepatocytes; Liver Neoplasms; Male; Pertussis Toxin; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Rats; Rats, Wistar; Signal Transduction; Tyrphostins | 2008 |
Leukocytoclastic vasculitis during treatment with the oral EGFR tyrosine kinase inhibitor erlotinib.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Erlotinib Hydrochloride; Female; Humans; Leg; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Vasculitis, Leukocytoclastic, Cutaneous | 2007 |
Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Hepatocellular; Clinical Trials as Topic; ErbB Receptors; Humans; Indoles; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2008 |
EGFR and VEGFR as potential target for biological therapies in HCC cells.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Delivery Systems; ErbB Receptors; Gefitinib; Humans; Liver Neoplasms; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2008 |
Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cadherins; Carcinoma, Hepatocellular; Cell Line, Tumor; Cetuximab; Enzyme Activation; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Insulin-Like Growth Factor II; Liver Neoplasms; Mesoderm; Mice; Mice, Inbred BALB C; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, IGF Type 1; STAT3 Transcription Factor; Vimentin | 2008 |
Crystal structures of rat thymidylate synthase inhibited by Tomudex, a potent anticancer drug.
Topics: Animals; Antimetabolites, Antineoplastic; Bacterial Proteins; Carcinoma, Hepatocellular; Computer Simulation; Crystallography, X-Ray; Deoxyuracil Nucleotides; Humans; Ligands; Models, Molecular; Protein Conformation; Quinazolines; Rats; Recombinant Proteins; Thiophenes; Thymidylate Synthase; Tumor Cells, Cultured | 1999 |
Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells.
Topics: Animals; Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Epidermal Growth Factor; ErbB Receptors; Hepatocyte Growth Factor; Humans; Liver Neoplasms; Phosphorylation; Protein Binding; Proto-Oncogene Proteins c-met; Quinazolines; Rats; Receptor Cross-Talk; Transforming Growth Factor alpha; Tumor Cells, Cultured; Tyrphostins | 2000 |
Biochemical and biological studies on 2-desamino-2-methylaminopterin, an antifolate the polyglutamates of which are more potent than the monoglutamate against three key enzymes of folate metabolism.
Topics: Acyltransferases; Aminopterin; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Division; Drug Administration Schedule; Folic Acid; Folic Acid Antagonists; Hydroxymethyl and Formyl Transferases; Leukemia L1210; Male; Methotrexate; Mice; Phosphoribosylaminoimidazolecarboxamide Formyltransferase; Phosphoribosylglycinamide Formyltransferase; Quinazolines; Thiophenes; Thymidylate Synthase; Tumor Cells, Cultured | 1992 |
Role of substrate depletion in the inhibition of thymidylate biosynthesis by the dihydrofolate reductase inhibitor trimetrexate in cultured hepatoma cells.
Topics: Carcinoma, Hepatocellular; Folic Acid; Liver Neoplasms; Pteroylpolyglutamic Acids; Quinazolines; Thymidine Monophosphate; Thymidylate Synthase; Thymine Nucleotides; Trimetrexate; Tumor Cells, Cultured | 1990 |
Serial serum AFP heterogeneity changes in patients with hepatocellular carcinoma during chemotherapy.
Topics: alpha-Fetoproteins; Carcinoma, Hepatocellular; Concanavalin A; Folic Acid; Humans; Liver Neoplasms; Quinazolines | 1986 |
Serum vitamin B12 levels in patients with primary hepatocellular carcinoma during treatment with CB3717.
Topics: Adult; Aged; alpha-Fetoproteins; Carcinoma, Hepatocellular; Female; Folic Acid; Follow-Up Studies; Humans; L-Lactate Dehydrogenase; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Quinazolines; Vitamin B 12 | 1987 |
Induction of remission in hepatocellular carcinoma with a new thymidylate synthase inhibitor, CB3717. A phase II study.
Topics: Adult; Aged; alpha-Fetoproteins; Carcinoma, Hepatocellular; Drug Evaluation; Female; Folic Acid; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Quinazolines; Remission Induction | 1987 |
Inhibition of the growth of human hepatocellular carcinoma in vitro and in athymic mice by a quinazoline inhibitor of thymidylate synthase, CB3717.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Deoxyuridine; Dose-Response Relationship, Drug; Folic Acid; Humans; In Vitro Techniques; Liver Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Quinazolines; Thymidine | 1986 |
A pleomorphic hepatocellular carcinoma with biochemical features of fibrolamellar hepatocellular carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Modality Therapy; Doxorubicin; Etoposide; Female; Folic Acid; Humans; Liver Neoplasms; Neurotensin; Quinazolines; Vitamin B 12 | 1986 |
The apparent induction of thymidylate synthetase by amethopterin.
Topics: Animals; Aspartic Acid; Benzoates; Carcinoma, Hepatocellular; Enzyme Induction; Folic Acid; Hepatectomy; Liver; Liver Neoplasms; Liver Regeneration; Methotrexate; Methyltransferases; Neoplasms, Experimental; Quinazolines; Rats; Thymine Nucleotides; Uracil Nucleotides | 1971 |